Healthcare policy shifts drive medication access improvements while new treatment advances emerge for myeloma, Alzheimer's, and multiple sclerosis

NHS England approves fampridine, the first mobility-enhancing drug for multiple sclerosis patients, reversing a 2022 NICE rejection now that the medication is off patent and bringing England into line with the rest of the UK.

Adult ADHD prescriptions surge 40% annually according to NHS figures, prompting an independent review to investigate the drivers behind the dramatic increase in demand for ADHD medications.

Lipid-lowering drug obicetrapib demonstrates the greatest reductions in Alzheimer's biomarker p-tau217 among APOE4 carriers, establishing rationale for initiating an Alzheimer's prevention trial.

Pharmacy associations criticize the government for excluding high street pharmacies from another round of business rates cuts while extending relief to pubs and live music venues.

Asthma patients with persistent airflow limitation face nearly twice the risk of severe exacerbations and exhibit distinct patterns of lung function decline compared to those without this limitation.

Researchers advance efforts to reduce immune suppression in islet cell transplants through development of less-toxic immunosuppressive regimens and gene editing approaches that could eliminate the need for immune suppression entirely.

An FDA approval combined with striking CAR T data creates contentious debate among myeloma experts regarding optimal treatment strategy for smoldering myeloma cases.

Hearing checks in infants enhance detection of cytomegalovirus infections, with experts continuing to advocate for universal newborn CMV screening programs.